Towards a Cancer Mission in Horizon Europe

Anton Berns; Ulrik Ringborg; Alexander Eggermont; Michael Baumann; Fabien Calvo; Angelika Eggert; Carolina Espina; Douglas Hanahan; Denis Lacombe; Francesco de Lorenzo; Simon Oberst; Thierry Philip; Joachim Schüz; Josep Tabernero; Julio E. Celis

doi:10.1002/1878-0261.12585

Towards a Cancer Mission in Horizon Europe

Anton Berns, Ulrik Ringborg, Alexander Eggermont, Michael Baumann, Fabien Calvo, Angelika Eggert, Carolina Espina, Douglas Hanahan, Denis Lacombe, Francesco de Lorenzo, Simon Oberst, Thierry Philip, Joachim Schüz, Josep Tabernero, Julio E. Celis

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

3 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	2301-2304
Aantal pagina's	4
Tijdschrift	Molecular Oncology
Volume	13
Nummer van het tijdschrift	11
DOI's	https://doi.org/10.1002/1878-0261.12585
Status	Gepubliceerd - 1 nov. 2019
Extern gepubliceerd	Ja

Toegang tot document

10.1002/1878-0261.12585

Citeer dit

@article{3c7b1347ebfd4adabf893b92b6c9d46e,

title = "Towards a Cancer Mission in Horizon Europe",

author = "Anton Berns and Ulrik Ringborg and Alexander Eggermont and Michael Baumann and Fabien Calvo and Angelika Eggert and Carolina Espina and Douglas Hanahan and Denis Lacombe and {de Lorenzo}, Francesco and Simon Oberst and Thierry Philip and Joachim Sch{\"u}z and Josep Tabernero and Celis, {Julio E.}",

note = "Funding Information: Carolina Espina and Joachim Sch{\"u}z state: where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization. Michael Baumann states: In the past 5 years, Dr. Baumann attended an advisory board meeting of MERCK KGaA (Darmstadt), for which the University of Dresden received a travel grant. He further received funding for his research projects and for educational grants to the University of Dresden by Teutopharma GmbH (2011–2015), IBA (2016), Bayer AG (2016–2018), Merck KGaA (2014–2030), Medipan GmbH (2014–2018). For the German Cancer Research Center (DKFZ, Heidelberg) Dr. Baumann is on the supervisory boards of HI‐STEM gGmbH (Heidelberg). Dr. Baumann, as former chair of OncoRay (Dresden) and present CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg), was or is responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia, worldwide. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including the DKFZ‐PSMA617 related patent portfolio and similar IP portfolios. Dr. Baumann confirms that none of the above funding sources were involved in the preparation of this paper. Other authors declare no conflict of interest. ",

year = "2019",

month = nov,

day = "1",

doi = "10.1002/1878-0261.12585",

language = "English",

volume = "13",

pages = "2301--2304",

journal = "Molecular Oncology",

issn = "1574-7891",

publisher = "John Wiley and Sons Ltd",

number = "11",

}

TY - JOUR

T1 - Towards a Cancer Mission in Horizon Europe

AU - Berns, Anton

AU - Ringborg, Ulrik

AU - Eggermont, Alexander

AU - Baumann, Michael

AU - Calvo, Fabien

AU - Eggert, Angelika

AU - Espina, Carolina

AU - Hanahan, Douglas

AU - Lacombe, Denis

AU - de Lorenzo, Francesco

AU - Oberst, Simon

AU - Philip, Thierry

AU - Schüz, Joachim

AU - Tabernero, Josep

AU - Celis, Julio E.

N1 - Funding Information: Carolina Espina and Joachim Schüz state: where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization. Michael Baumann states: In the past 5 years, Dr. Baumann attended an advisory board meeting of MERCK KGaA (Darmstadt), for which the University of Dresden received a travel grant. He further received funding for his research projects and for educational grants to the University of Dresden by Teutopharma GmbH (2011–2015), IBA (2016), Bayer AG (2016–2018), Merck KGaA (2014–2030), Medipan GmbH (2014–2018). For the German Cancer Research Center (DKFZ, Heidelberg) Dr. Baumann is on the supervisory boards of HI‐STEM gGmbH (Heidelberg). Dr. Baumann, as former chair of OncoRay (Dresden) and present CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg), was or is responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia, worldwide. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including the DKFZ‐PSMA617 related patent portfolio and similar IP portfolios. Dr. Baumann confirms that none of the above funding sources were involved in the preparation of this paper. Other authors declare no conflict of interest.

PY - 2019/11/1

Y1 - 2019/11/1

UR - http://www.scopus.com/inward/record.url?scp=85074280152&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12585

DO - 10.1002/1878-0261.12585

M3 - Article

C2 - 31670486

AN - SCOPUS:85074280152

SN - 1574-7891

VL - 13

SP - 2301

EP - 2304

JO - Molecular Oncology

JF - Molecular Oncology

IS - 11

ER -